PHARMAPLAN returns
TTP AG buys European engineering companies from NNE A/S
Frankfurt am Main / Copenhagen (ots) - TTP AG, Frankfurt/Main and
it's subsidiary TTP GmbH, has signed an agreement with the Danish NNE
A/S in Copenhagen for the purchase of three NNE subsidiaries based in
Switzerland, Germany and Belgium.
TTP AG is an operational holding company specialising in
production-related engineering services for the process industry. It
is the majority shareholder of TRIPLAN Aktiengesellschaft, based in
Bad Soden am Taunus, an engineering service company with focus on the
life science, chemical and petrochemical sectors.
it's subsidiary TTP GmbH, has signed an agreement with the Danish NNE
A/S in Copenhagen for the purchase of three NNE subsidiaries based in
Switzerland, Germany and Belgium.
TTP AG is an operational holding company specialising in
production-related engineering services for the process industry. It
is the majority shareholder of TRIPLAN Aktiengesellschaft, based in
Bad Soden am Taunus, an engineering service company with focus on the
life science, chemical and petrochemical sectors.
NNE specialises in engineering and consulting services,
particularly for major projects in the growth markets of
biotechnology and pharmaceuticals, and covers all areas of EPCM
(Engineering, Procurement, Construction Management) projects.
TTP AG plans to continue managing the three NNE subsidiaries in
the European market as a largely independent company in the
pharmaceutical and life science sector, and to revive the PHARMAPLAN
brand name, under which the companies were known until 2017.
Joachim Grendel, the CEO of TTP AG: "TRIPLAN's local presence,
competencies, business areas and value chains and those of the future
PHARMAPLAN complement each other perfectly. This leads to a
sustainably better market and competitive position thanks to growth
synergies in Europe - even in the face of deteriorating economic
conditions and market environments. Together we comprise one of the
leading medium-sized engineering companies for the process industry
in Europe."
Dr. Andreas Bonhoff, CFO of TRIPLAN AG: "The names TRIPLAN and
PHARMAPLAN stand for excellent engineering culture, which we want to
preserve respectfully together with our employees and further develop
in a quality-oriented manner. PHARMAPLAN and TRIPLAN are to present
themselves confidently as European companies, seize new market
opportunities and at the same time act as attractive employers in the
top league."
Jesper Kløve, the CEO of NNE A/S: "The transaction is a great
strategic match for both parties, where NNE A/S strategy is to
intensify the geographical focus on the markets and customers of
Denmark, the US and India. I strongly believe that TTP AG will create
a bright future for our colleagues in Switzerland, Germany and
Belgium, by further developing the strong local presence in the
markets"
The acquisition is expected to take effect at the end of March
2019. The parties have agreed not to disclose the purchase price. The
NNE companies in Germany, Switzerland and Belgium have around 360
employees and generated sales of EUR 61 million in 2018. Triplan AG
particularly for major projects in the growth markets of
biotechnology and pharmaceuticals, and covers all areas of EPCM
(Engineering, Procurement, Construction Management) projects.
TTP AG plans to continue managing the three NNE subsidiaries in
the European market as a largely independent company in the
pharmaceutical and life science sector, and to revive the PHARMAPLAN
brand name, under which the companies were known until 2017.
Joachim Grendel, the CEO of TTP AG: "TRIPLAN's local presence,
competencies, business areas and value chains and those of the future
PHARMAPLAN complement each other perfectly. This leads to a
sustainably better market and competitive position thanks to growth
synergies in Europe - even in the face of deteriorating economic
conditions and market environments. Together we comprise one of the
leading medium-sized engineering companies for the process industry
in Europe."
Dr. Andreas Bonhoff, CFO of TRIPLAN AG: "The names TRIPLAN and
PHARMAPLAN stand for excellent engineering culture, which we want to
preserve respectfully together with our employees and further develop
in a quality-oriented manner. PHARMAPLAN and TRIPLAN are to present
themselves confidently as European companies, seize new market
opportunities and at the same time act as attractive employers in the
top league."
Jesper Kløve, the CEO of NNE A/S: "The transaction is a great
strategic match for both parties, where NNE A/S strategy is to
intensify the geographical focus on the markets and customers of
Denmark, the US and India. I strongly believe that TTP AG will create
a bright future for our colleagues in Switzerland, Germany and
Belgium, by further developing the strong local presence in the
markets"
The acquisition is expected to take effect at the end of March
2019. The parties have agreed not to disclose the purchase price. The
NNE companies in Germany, Switzerland and Belgium have around 360
employees and generated sales of EUR 61 million in 2018. Triplan AG